Printed from Voxsanity (voxsanity.com.au) — NCT06887127 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Rheumatoid Arthritis
Phase 3 Rheumatoid Arthritis Trial, Recruiting
NCT06887127
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who completed the earlier related study (called TLL-018-301) within the past 3 months
- People aged 18 to 75 years old at the time of giving consent
- Women who could become pregnant must have a negative pregnancy test before joining and must not currently be pregnant or breastfeeding
- All participants and their partners must use effective birth control from the first dose to at least 90 days after the last dose, and must not donate sperm or eggs from the screening period until at least 6 months after the last dose
- People who are able to understand the consent form and are willing to sign it and take part voluntarily
Who may not be able to join:
- People who had a severe allergic reaction to the study drug during the earlier TLL-018-301 study
- People who developed shingles (herpes zoster), a major heart or blood vessel event, blood clots, or a lymph system disorder between the earlier study and the screening for this study
- People who have a significant ongoing heart, lung, or other serious or unstable health condition that the study doctor considers a safety risk
- People whose blood or other lab test results are significantly abnormal at the time of screening
- People who have taken certain medications — including traditional Chinese medicines, certain arthritis drugs (csDMARDs), immune-suppressing drugs, strong opioid painkillers, or other JAK inhibitor drugs — within 1 week before taking the first dose in this study (confirm with trial site for the full list)
- People who were treated with certain other medications — including leflunomide, biological arthritis drugs (bDMARDs), interferon, or other injected immune-suppressing drugs — at any point between the earlier study and this study's screening
- People who received a live vaccine within 2 months before the first dose, or who plan to receive a live vaccine at any point during the study
- People with active tuberculosis (TB) that has not been clinically cured, suspected TB symptoms as judged by the study doctor, or latent (inactive) TB that has not been treated with a preventive treatment course within the past 3 years or where a full course of treatment was not completed
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
Registry
ClinicalTrials.gov
Start date
10 March 2025
Est. completion
31 December 2026
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Number of occurrences and Percentage of Participants with AEs and SAEs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.